Novo Nordisk CEO: Wegovy not only reduces your weight, but it also shows cardiovascular benefits
Mike Doustdar, Novo Nordisk president and CEO, joins ‘Mad Money’ host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.
Vanessa Williams Has Been Taking a GLP-1 for Weight Loss for 2 Years
Vanessa Williams is opening up about her health. The 62-year-old Ugly Betty actress and singer revealed she’s been taking a GLP-1 for weight loss for the past two years. Vanessa got candid in a new cover story, explaining that she began Mounjaro, a GLP-1 medication for people with Type 2 diabetes (which is also used […]
诺和诺德预计口服药物将在2030年前占据GLP-1减肥药市场三分之一以上份额
Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030 (www.reuters.com) 06:02
Stopping GLP-1 Weight Loss Drugs Leads to Fast Rebound in Weight and Heart Risks, Study Warns
Weight loss drugs have shown impressive short-term results, but new research suggests their benefits may be difficult to sustain once treatment ends. Stopping treatment with weight loss medications is associated with gradual weight gain and a loss of earlier improvements in heart and metabolic health, according to new research published by The BMJ. The study […]
Are GLP-1s the Best Defense Against Excessive Drinking?
Treatment of alcohol use disorder is shaping up to be another win for the GLP-1 weight-loss drugs. Medscape
What are GLP-3s? Weight loss drugs are more effective than current popular jabs in clinical trials
One in eight Americans are taking a GLP-1 drug, a recent poll found
Novo CEO sees obesity pill opening doors to new markets
Novo Nordisk A/S’s obesity pill will allow it to tap into a massive population of patients that have not yet taken GLP-1s , the drugmaker’s chief executive said. The pill version of its blockbuster obesity shot Wegovy will expand the market for these drugs, CEO Mike Doustdar said at an Endpoints event in San Francisco […]
Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030 – Reuters
Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030 Reuters
New Year, New Strategy: Navigating Weight Loss ETFs
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This class of drugs has fundamentally altered the healthcare sector’s growth projections. As the market matures, advisors are increasingly evaluating weight loss ETFs to capture […]
Dr. Drew Says GLP-1 Drugs May Have Helped Nick Reiner, But It’s Delicate Balance
Nick Reiner’s weight gain set him on a murderous path, but it didn’t have to be that way … just ask Dr. Drew. The good doc joined us on “TMZ Live” Monday and told us Nick likely would have benefited from being prescribed weight-loss drugs to…